Tradestie Institutional Equity Comparison Engine
AKTX vs EQ โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EQ Overall Edge
EQ Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Equillium, Inc. Common Stock (EQ) driven by superior Valuation, Options & Structure while AKTX counters with relative strength in Momentum & Technical. Fundamentally, AKTX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus EQ at 1.5x Forward P/E and 0.0% operating margin (-52.3% YoY). In options structure, AKTX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against EQ sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
EQ
AKTX N/M vs EQ 1.5x Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -52.3%
Momentum & Technical Winner
AKTX
1Y +1163.7% vs +12.0% ยท 52W Pos 23% vs 11%
Options & Structure Winner
EQ
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (100th %ile IV)
AKTX
NASDAQ
Akari Therapeutics plc ADR (0.01 USD)
Pharmaceutical Preparations
$6.71
+0.9% 1D
Market Cap
$16.3M
1M Return
-23.4%
1Y Return
+1163.65%
Forward P/E
N/M
Unified AI Score
53.0 / 100
HOLD
Tech 65.0
Fund 52.0
Flow 50.0
Mom 50.0
EQ
NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap
$90.6M
1M Return
-21.13%
1Y Return
+12.0%
Forward P/E
1.5x
Unified AI Score
48.0 / 100
HOLD
Tech 30.0
Fund 51.0
Flow 63.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
AKTX +1163.65%
EQ +12.0%
Spread: +1151.65 pp (AKTX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
AKTX TTM Op. Margin: 0.0%
EQ TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKTX vs EQ. Trailing 12-month operating profitability (AKTX 0.0% vs EQ 0.0%) and valuation multiples (AKTX N/M vs EQ 1.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AKTX | EQ | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $16.3M | $90.6M | Larger Scale | EQ |
| Trailing P/E Ratio Valuation | N/M | 1.5x | Lower Multiple | EQ |
| Forward P/E Ratio Valuation | N/M | 1.5x | Lower Multiple | EQ |
| Revenue Growth (YoY) Growth | +0.0% | -52.3% | Higher Growth | AKTX |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -146.3% | -59.0% | Higher ROE | EQ |
| 52-Week Range Position Momentum | 23% ($0โ$29) | 11% ($1โ$4) | Stronger Trend | AKTX |
| Beta / 30D Volatility Risk Regime | 81.68ฮฒ ยท 145% Vol | 1.53ฮฒ ยท 93% Vol | Lower Realized Risk | EQ |
| Unified Institutional Score Composite Signal | 53.0 / 100 (HOLD) | 48.0 / 100 (HOLD) | Higher Composite | AKTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full AKTX vs EQ Buy Guide
AKTX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
EQ
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither AKTX nor EQ registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.